Senior Director, Investor Relations

As the Senior Director of Investor Relations (IR) will serve as the company's primary IR lead in the United States, representing the company to institutional investors, and other stakeholders in the largest biopharma investment market globally. You will report in to and work closely with the Head of Investor Relations (based in Australia) to design and execute a proactive, best-in-class investor relations strategy aligned with the company's global growth trajectory, therapeutic pipeline, and ASX listing obligations.

You will bring a deep understanding of capital markets, biopharma sector dynamics, and the ability to effectively communicate the company's value proposition to sophisticated US-based investors while ensuring global messaging alignment.

Main Responsibilities and Accountabilities:

Investor Engagement & Market Presence

• Serve as the primary US-based spokesperson for institutional investors, analysts, and other capital markets stakeholders.
• Build and maintain strong, trust-based relationships with key investors across the US, including biopharma-specialist funds, generalist funds, and crossover investors. Lead non-deal roadshows, conference participation, and investor events in North America, working closely with the Head of IR and executive leadership.
• Act as an early warning system on US investor sentiment, competitive positioning, and capital markets trends.

• Partner with the Head of IR to design and deliver the global investor relations strategy, tailoring it for US investor audiences.
• Ensure consistent messaging across all investor communications including earnings releases, investor presentations, Q&A briefings, and ESG reports.
• Translate complex scientific, regulatory, and commercial developments into clear, compelling investment narratives.

• Support 6 monthly earnings cycle: preparation of results materials, scripts, Q&A, and post-results investor follow-up in the US time zone.
• Drive analyst engagement: manage coverage initiation, consensus tracking, and respond to analyst queries.
• Develop high-impact investor day agendas, presentations, and senior leadership briefings for US investor events.
• Coordinate with Corporate Communications and Legal/Compliance on disclosure, ASX listing rule requirements. and support ADR Based engagement.

• Monitor peer company performance, sector news flow, and relevant biopharma indices to contextualize investor conversations.
• Provide insights to the Executive Team and Board on investor sentiment, sector trends, valuation drivers, and competitive positioning.
• Develop and maintain US investor targeting frameworks to broaden and diversify the shareholder base.

• Partner with the CEO, CFO, and Head of IR to prepare senior leaders for investor meetings, conferences, and earnings calls.
• Work cross-functionally with Group Finance, R&D, Commercial & Medical, Company Secretary, and Legal to gather information, ensure disclosure accuracy, and create a two-way flow of market intelligence into the business.
• Collaborate with Sustainability/ESG teams to incorporate ESG performance and reporting as required
• Contribute to the any other projects as require from time to time.

• Post-graduate qualification in relevant discipline essential.
• 10+ years of experience in Investor Relations, Equity Research, Corporate Development, or Investment Banking, with a strong focus on biopharma/pharma/healthcare.
• Deep understanding of US capital markets and institutional investor landscape.
• Track record of leading investor engagement programs and building long-term investor relationships.
• Exceptional financial literacy, including comfort with P&L, balance sheet, cash flow, and valuation modelling.
• Ability to distill complex scientific/regulatory information into clear investment narratives.
• Strong written, oral and storytelling communication skills, with executive presence and board-level influencing skills.
• This is a Hybrid position requiring 3 days a week onsite in KOP

• Preferred:
• Prior experience at a dual-listed or global biopharma company (ASX/NASDAQ or similar).
• Existing relationships with key US biopharma analysts and investors